rupatadine has been researched along with prifelone in 1 studies
| Studies (rupatadine) | Trials (rupatadine) | Recent Studies (post-2010) (rupatadine) | Studies (prifelone) | Trials (prifelone) | Recent Studies (post-2010) (prifelone) |
|---|---|---|---|---|---|
| 116 | 43 | 62 | 6 | 0 | 1 |
| Protein | Taxonomy | rupatadine (IC50) | prifelone (IC50) |
|---|---|---|---|
| Polyunsaturated fatty acid 5-lipoxygenase | Homo sapiens (human) | 4.8 | |
| Prostaglandin G/H synthase 1 | Homo sapiens (human) | 0.2529 | |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | 0.2529 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Morphy, R; Rankovic, Z | 1 |
1 review(s) available for rupatadine and prifelone
| Article | Year |
|---|---|
Designed multiple ligands. An emerging drug discovery paradigm.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Allergic Agents; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents; Antihypertensive Agents; Antipsychotic Agents; Chemistry, Pharmaceutical; Dopamine D2 Receptor Antagonists; Drug Design; Humans; Ligands; Metabolic Diseases; Peroxisome Proliferator-Activated Receptors; Receptors, Histamine H1; Selective Serotonin Reuptake Inhibitors | 2005 |